Controlling Nutritional Status (CONUT) score is a prognostic marker in III-IV NSCLC patients receiving first-line chemotherapy
- Location
-
Deutsche Nationalbibliothek Frankfurt am Main
- Extent
-
1 Online-Ressource.
- Language
-
Englisch
- Bibliographic citation
-
Controlling Nutritional Status (CONUT) score is a prognostic marker in III-IV NSCLC patients receiving first-line chemotherapy ; volume:23 ; number:1 ; day:9 ; month:3 ; year:2023 ; pages:1-10 ; date:12.2023
BMC cancer ; 23, Heft 1 (9.3.2023), 1-10, 12.2023
- Creator
-
Zhang, Yi
Kong, Fei-Fei
Zhu, Zheng-Qiu
Shan, Hai-Xia
- Contributor
-
SpringerLink (Online service)
- DOI
-
10.1186/s12885-023-10682-z
- URN
-
urn:nbn:de:101:1-2502250937382.545183109242
- Rights
-
Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Last update
-
15.08.2025, 7:30 AM CEST
Data provider
This object is provided by:
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Associated
- Zhang, Yi
- Kong, Fei-Fei
- Zhu, Zheng-Qiu
- Shan, Hai-Xia
- SpringerLink (Online service)
Other Objects (12)
ASSESSMENT OF NUTRITIONAL STATUS OF PATIENTS RECEIVING CHEMOTHERAPY
Long-term virological outcome in children receiving first-line antiretroviral therapy
Correction to: Osimertinib as first-line therapy in advanced NSCLC: a profile of its use
Role of antiangiogenic agents in first-line treatment for advanced NSCLC in the era of immunotherapy
Comparison between Vinorelbine–Carboplatin and Vinorelbine–Cisplatin in Stage III–IV EGFR Mutations-Negative NSCLC
Multi-institutional prognostic modeling of survival outcomes in NSCLC patients treated with first-line immunotherapy using radiomics
The relationship between RRM1 gene polymorphisms and effectiveness of gemcitabine-based first-line chemotherapy in advanced NSCLC patient
Real-world experience of first-line afatinib in patients with EGFR-mutant advanced NSCLC: a multicenter observational study
Pemetrexed-based first-line chemotherapy had particularly prominent objective response rate for advanced NSCLC: A network meta-analysis
Optimal first-line treatment for EGFR-mutated NSCLC: a comparative analysis of osimertinib and second-generation EGFR-TKIs
Sex and survival outcomes in patients with renal cell carcinoma receiving first-line immune-based combinations
Predictive significance of circulating tumor DNA against patients with T790M-positive EGFR-mutant NSCLC receiving osimertinib
ASSESSMENT OF NUTRITIONAL STATUS OF PATIENTS RECEIVING CHEMOTHERAPY
Long-term virological outcome in children receiving first-line antiretroviral therapy
Correction to: Osimertinib as first-line therapy in advanced NSCLC: a profile of its use
Role of antiangiogenic agents in first-line treatment for advanced NSCLC in the era of immunotherapy
Comparison between Vinorelbine–Carboplatin and Vinorelbine–Cisplatin in Stage III–IV EGFR Mutations-Negative NSCLC
Multi-institutional prognostic modeling of survival outcomes in NSCLC patients treated with first-line immunotherapy using radiomics
The relationship between RRM1 gene polymorphisms and effectiveness of gemcitabine-based first-line chemotherapy in advanced NSCLC patient
Real-world experience of first-line afatinib in patients with EGFR-mutant advanced NSCLC: a multicenter observational study
Pemetrexed-based first-line chemotherapy had particularly prominent objective response rate for advanced NSCLC: A network meta-analysis
Optimal first-line treatment for EGFR-mutated NSCLC: a comparative analysis of osimertinib and second-generation EGFR-TKIs
Sex and survival outcomes in patients with renal cell carcinoma receiving first-line immune-based combinations
Predictive significance of circulating tumor DNA against patients with T790M-positive EGFR-mutant NSCLC receiving osimertinib
ASSESSMENT OF NUTRITIONAL STATUS OF PATIENTS RECEIVING CHEMOTHERAPY
Long-term virological outcome in children receiving first-line antiretroviral therapy
Correction to: Osimertinib as first-line therapy in advanced NSCLC: a profile of its use
Role of antiangiogenic agents in first-line treatment for advanced NSCLC in the era of immunotherapy
Comparison between Vinorelbine–Carboplatin and Vinorelbine–Cisplatin in Stage III–IV EGFR Mutations-Negative NSCLC
Multi-institutional prognostic modeling of survival outcomes in NSCLC patients treated with first-line immunotherapy using radiomics
The relationship between RRM1 gene polymorphisms and effectiveness of gemcitabine-based first-line chemotherapy in advanced NSCLC patient
Real-world experience of first-line afatinib in patients with EGFR-mutant advanced NSCLC: a multicenter observational study
Pemetrexed-based first-line chemotherapy had particularly prominent objective response rate for advanced NSCLC: A network meta-analysis
Optimal first-line treatment for EGFR-mutated NSCLC: a comparative analysis of osimertinib and second-generation EGFR-TKIs
Sex and survival outcomes in patients with renal cell carcinoma receiving first-line immune-based combinations